NasdaqGS:KRYSBiotechs
Krystal Biotech (KRYS): Assessing Valuation Following Strong Earnings Surge and Investor Optimism
Krystal Biotech (KRYS) just posted third quarter earnings that far outpaced last year. The company reported a sharp jump in net income and earnings per share for both the quarter and year-to-date. This strong performance quickly caught investors’ attention.
See our latest analysis for Krystal Biotech.
After this earnings jump, Krystal Biotech's share price quickly reflected renewed optimism, notching a 29.71% share price return year-to-date and a strong 35.93% gain over the last 90 days...